CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), announced that Sudhir Agrawal, D. Phil., Chief Executive Officer and Chief Scientific Officer, will present today an overview of TLR antagonists and their applications in autoimmune and inflammatory diseases in a talk entitled “Antagonists of Toll-like Receptor 7 and 9 for Autoimmune and Inflammatory Diseases”. The presentation will be made during a session called “Toll-Like Receptor Agonists and Antagonists for the Therapy of Inflammation and Infection” during the 8th World Congress on Trauma, Shock, Inflammation and Sepsis (TSIS 2010) in conjunction with the 23rd SIS-Europe Congress on Surgical Infections and the 2nd Interdisciplinary Summit on Inflammation, in Munich, Germany, from March 9-13, 2010.
